Kanagawa, Japan, 30 September 2022 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kanae Gamo, Ph.D., Chief Scientific Officer of FIMECS, will make a presentation at the 5th Targeted Protein Degradation Summit (25-28 October 2022 in Boston, MA, USA). Title is “Function First Strategy that Enables Efficient & Productive Generation of Degraders”. In this presentation, improvement of the RaPPIDS™ platform for expanding the landscape of E3 ligases by function-first approach that make degrader discovery more efficient will be introduced.
For more information:https://proteindegradation.com/
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
About RaPPIDS™
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.
# # #
FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
Email: info@fimecs.com